Omidenepag Pharmaceutical Preparation for Resistant Glaucoma
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for a pharmaceutical preparation that effectively treats or prevents glaucoma or ocular hypertension in patients who have inadequate responses to other glaucoma or ocular hypertension therapeutic agents.
Innovation Solution
A pharmaceutical preparation containing omidenepag, an ester thereof, or a salt thereof as the active ingredient, which is administered to patients with inadequate efficacies of other glaucoma or ocular hypertension therapeutic agents, providing an excellent intraocular pressure lowering efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional glaucoma therapeutic agents (such as latanoprost, timolol, brimonidine) are used for treatment, then initial intraocular pressure lowering effect is achieved, but treatment efficacy becomes inadequate in resistant patients
Solution Approach 1:
The patent applies parameter changes by switching from conventional glaucoma medications to a different chemical class (pyridyl aminoacetic acid compounds) with distinct pharmacological properties. This change in chemical structure and mechanism of action parameters enables effective treatment in patients who showed inadequate response to traditional agents, thereby resolving the contradiction between initial efficacy and treatment resistance.
2Reliability
If multiple glaucoma therapeutic agents are combined to enhance efficacy, then intraocular pressure lowering effect is improved, but treatment complexity increases
Solution Approach 1:
The patent applies universality by developing a single pyridyl aminoacetic acid compound that can serve as an effective monotherapy or combination therapy for glaucoma. This compound provides broad-spectrum efficacy across different patient populations, including those resistant to conventional agents, thereby reducing the need for complex multi-agent regimens while maintaining high intraocular pressure lowering efficacy.
Data Source
AI summary
The present invention aims to find a pharmaceutical preparation which treats or prevents glaucoma or ocular hypertension and is effective for patients with inadequate efficacies of glaucoma or ocular hypertension therapeutic agents. It has been found that omidenepag, an ester thereof, or a salt thereof has an excellent intraocular pressure lowering efficacy on patients with inadequate efficacies of other glaucoma or ocular hypertension therapeutic agents. Therefore, the omidenepag, the ester thereof, or the salt thereof of the present invention is useful as a pharmaceutical preparation which can treat or prevent glaucoma or ocular hypertension even in patients with inadequate efficacies of other glaucoma or ocular hypertension therapeutic agents.